With already five EGFR TKIs to choose from, is there room for one more? Janssen thinks there is, betting on a combination strategy to defeat osimertinib
With already five EGFR TKIs to choose from, is there room for one more? Janssen thinks there is, betting on a combination strategy to defeat osimertinib
Approval based on the NSCLC cohorts included in the ARROW phase 1/2 study. Data from thyroid cancer cohorts has been filed; PDUFA in February 2021
As expected, the majority of ESMO orals will be IO related. As for small molecules, oral presentations include the usual line up of targets, but also some things new or noteworthy.
Next generation TKIs are developed to target a broader spectrum of EGFR mutations. But can they overcome the challenges presented by exon 20 insertion mutations?
Asciminib significantly improved the Molecular Response Rate at 24 wks vs bosutinib in previously treated CML (Novartis press release)
FDA BTD and NDA filing based on data from ongoing phase 2 VISION study; no PDUFA date mentioned (EMD press release)
